The Center for Biophysical Sciences and Engineering (CBSE) (University-Wide Interdisciplinary Research Center)

Director:  Larry DeLucas, OD, PhD, DSc

Established:  1986

 

Mission and Demographics

The Center for Biophysical Sciences and Engineering (CBSE) is dedicated to determination of structure-function relationships of biological molecules supporting drug design methodology for chronic and infectious diseases.  With over 100 members including 12+ PhD level crystallographers, the CBSE is one of the largest x-ray crystallography units in the structural biology community.

Center Research

The CBSE has established research expertise in structural biology to reflect its approach to structure based drug design and the impact of structural genomics and proteomics in drug discovery.  The facility provides structural biology support from cloning and expression through structure determination and combinatorial chemistry for researchers interested in macromolecular structure-function relationships and drug discovery via intelligent combinatorial design.  Protein structural information is used for the discovery and synthesis of complimentary compounds that augment or inhibit the protein's biological activity for drug discovery applications.  Our state-of-the-art approach to developing small molecule drugs includes an integrated platform of high-throughput (HTP) technologies providing structural solutions for both aqueous and membrane proteins of interest.  Current drug development programs supported by the facility focus on cancer, infectious diseases, cardiovascular disease, bacterial infections, and immune response.  The CBSE has a special interest in crystallizing and solving membrane protein structures in particular.

The CBSE operates a HTP Protein Expression and Purification Facility for cloning and expressing proteins in both prokaryotic and eukaryotic host systems on entire genomes, providing molecular biology scale production and access to a core facility for large scale growth of bacterial cultures.  The CBSE has expertise and ability to produce proteins of interest for researchers in e. coli, baculovirus, yeast, and the lentivirus system.  Recombinatorial cloning and streamlined approaches for refolding and purification of proteins are employed to optimize results.

The HTP Protein Crystallization Facility minimizes the time and amount of protein sample a researcher needs to obtain diffraction quality crystals for structure determination.  The Crystallization Facility includes a fully integrated laboratory with HTP systems capable of rapidly generating hundreds of specialized solutions for screens in nanoliter to microliter volumes.  The laboratory maintains a total of four HTP systems (employing hanging drop, sitting drop, batch, microchip free interface diffusion and capillary counter diffusion methods) for crystallization and co-crystallization trials, thus increasing throughput to over 20,000 experiments per day using nanoliter to microliter volumes.  Sample requirements for initial screens start at just 600 µg of protein.  The HTP protein crystallization and Co-Crystallization screening facility utilizes the following integrated platform of systems:

·         A HTP automated system for rapid generation and optimization of specialized solutions used in crystallization screens (Recipe Maker™).

·         A new (2008) Rigaku Phoenix RE Liquid Handling System for high throughput low volume protein crystallization experimentation.

·         Two automated HTP liquid dispensing systems for submicroliter volumes (the custom built NanoScreen™ and the commercial Cartesian HoneyBee™ System).

·         An automated microchip system for free interface diffusion crystallization along with an automated imaging station for microchips (a.k.a. the Fluidigm Topaz Microchip System™). 

·         An automated HTP capillary counter diffusion system (the HoneyComb by Genomic Solutions™).

·         A HTP automated system for optical recognition and scoring of crystals (Crystal Score™).

·         A dynamically controlled crystal growth kinetic system for optimization of crystal growth (Vapor Pro™).

·         The CBSE has also developed a neural network (utilizing a predictive algorithm) for “in silico” screening of conditions.  This neural network optimizes screening conditions and has been shown to produce additional conditions that yield larger, more suitable crystals for x-ray analysis. Success has been demonstrated with the use of this virtual screening program for the optimization of crystallization conditions, thus reducing amount of sample and number of experiments needed to define high quality crystal growth.  This technology supports efforts to find new or optimize present conditions that improve crystal growth for both soluble and in particular membrane proteins such as GPCR’s and Ion Channels.

·         HTP Self Interaction Chromatography, a customized HPLC system for accurate protein-protein interaction experiments for the determination of second virial coefficient measurements of proteins.  Improved crystallization parameters for proteins as well as optimizing solutions for the stabilization of protein pharmaceutical formulations represents examples of protein solution phenomena that can be measured with thermodynamics measurements of protein-protein interactions.  We can measure PPI through the determination of the second virial coefficient.  The CBSE has developed a - HTP analytical method and automated system that allows users to quickly determine optimal solutions.

 

These complimentary technologies position the CBSE to rapidly pursue structural information for every protein in a target genome.  Researchers at the CBSE have successfully pioneered new technologies in support of drug discovery programs that have led to the design of pharmaceuticals for preclinical and clinical trials developed to treat chronic and infectious diseases such as T-cell mediated diseases, acute coronary syndromes, influenza, Bacillus anthracis (anthrax infection), bacterial vaginosis, and other emerging infections.  

The CBSE has unparalleled capacity in the area of collecting x-ray diffraction data and analyzing these coordinates for 3D structure determination of proteins and protein drug complexes.  Since 1997, UAB has been a member of the Southeast Regional Collaborative Access Team (SERCAT) with dedicated access to two of the most powerful beamlines at the Argonne National Laboratory in Chicago.  This access provides 15 or more days of dedicated access for UAB at the most powerful synchrotron facility in the U.S.  By using the multiple wavelengths (only available at synchrotrons), the structure of a large protein can be determined in one week or less with suitable crystals.  Frozen crystal samples can also be shipped to SER-CAT and diffraction data can be collected utilizing the SERCAT “Mail-in Crystallography” program.  This program provides the critical access to the high quality synchrotron beam lines that researchers need for structural proteomics and research collaborations with other academic, not-for-profit, pharmaceutical, and biotechnology partners. 

The Laboratory of Medicinal and Combinatorial Chemistry (LMCC) identifies and optimizes lead compounds against selected and newly defined biological targets.  The LMCC works with the x-ray crystal structure of protein drug targets to perform “in silico” virtual screening and protein structure-directed ligand design.  This capability has considerable advantages for the design and development of clinically relevant compounds for pharmaceutical design.  Two synthetic laboratories are specifically designed for parallel, solution phase chemistry and house the robotic synthesizer along with other equipment to support parallel library synthesis. 

The CBSE Biomolecular Physics laboratory provides complimentary techniques used by researchers in support of both crystallization and lead compound development.  The CBSE Biomolecular Analysis Group currently uses biocalorimetry data and other biophysical tools to advance the early stages of lead compound design and optimization when the focus is on improving affinity for the macromolecular target.  Calorimetry techniques determine relevant thermodynamic parameters necessary to correlate structure with energetics.  These energetic consequences per se, can affect the mechanism of action.  Knowledge of how these thermodynamic parameters of binding vary with different lead structures and chemical analogs can direct choices for further chemical modification.  The laboratory includes four high sensitivity calorimeters (isothermal and differential scanning calorimeters); two Biosensor BiaCore 2000; and an OLIS rapid scanning spectrophotometer for circular dichroism, fluorescence, fluorescence polarization and uv/vis for kinetic, stopped-flow, and temperature scanning.

      Isothermal Titration Calorimetry and Differential Scanning Calorimetry can advance research with applications in: 1) protein engineering, detecting misfolded domains; 2) proteomics, energetic domain architecture; 3) optimization of crystallization conditions, 4) biopharmaceutical formulations; 5) drug discovery: developing universal assay for lead identification, development; and 6) understanding the importance of functional groups, salvation, hydrophobicity, and conformation.

A HTP Screening Facility rapidly identifies active compounds in chemical libraries with high statistical accuracy to advance initial leads for drug design.  The facility provides a platform of flexibility and rich functionality for HTP research applications.  Numerous biochemical and molecular biology experiments are performed, such as compound library screening, enzymatic activity, ELISA, receptor binding, macromolecular interaction, protein expression, as well as protein folding and assembly.  The infrastructure of the HTP screening facility centers around a Beckman/Sagian integrated core robotic system enhanced with a custom software system.

The Center’s history also includes the designation in 1986 from NASA as a Research Partnership Center aimed at fostering the participation and investment of industry in the commercial development of space related projects.  The CBSE’s concentration in the area of protein structural information and the discovery/development of new drugs bridges the access of those interested in the effects of microgravity in scientific research.  This research will lead to beneficial health related discoveries for those traveling, working, and living in space.  

In 1990, the Engineering Division was brought in-house to develop new technologies and support the scientific community in the design and operation of both laboratory and microgravity experiments.  The Engineering Division is a full-service organization capable of providing technical services and turn-key systems to our customers.  Our capabilities in hardware and software development cover mechanical, electrical, and software design, fabrication, assembly, test, and operations.  As one of the nation's leading developers in cold stowage hardware for use in microgravity and exploration, the Engineering Division provides services in systems engineering, safety and verification documentation/closeout, crew training, launch-site support, mission operations, and recovery.  The Engineering Division offers expertise in the following areas: 1) Mechanical Hardware (prototype) Development; 2) Electrical Engineering; 3) Software Development; 4) Metrology; 5) Procurement, Fabrication and Assembly; 6) Research Machine Shop; and 7) Systems Engineering.

The Engineering Division occupies 18,000 square feet.  There is specialized facility space supports hardware assembly and system testing, remote operations for payloads on-board Shuttle or ISS, and computer/network internal support functions.  The following labs are ISO 9001:2000 Certified: 1) the Fabrication/Assembly/Test Labs, 2) the 100k Class Clean Room, 3) the Prototyping Lab, and 4) the Metrology Hardware machining and fabrication is performed through the Research Machine Shop and is available to the entire UAB community as well.

 

For additional information:

Director:  Larry DeLucas, OD, PhD, DSc

Email:  delucas@cbse.uab.edu

                 

 

Approved by:  Larry DeLucas, OD, PhD, DSc, Director

Date:  April 30, 2008

 

 

Click here to return to the SOM Research Web Site's home page.